Study Title
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Protocol ID
I3Y-MC-JPCS
Disease (Sub Disease)
Solid Tumours
Diagnosis Stage
Relapsed/refractory
Location
QLD, VIC, WA
Sponsor
Eli Lilly and Company
Links
Trial Status
Closed to Recruitment
Sites
Perth Children's Hospital
Royal Children's Hospital
Queensland Children's Hospital
Royal Children's Hospital
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 21 Years
International registry ID's
NCT04238819
| Study Title | A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab GM-CSF Irinotecan and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C) |
|---|---|
| Protocol ID | I3Y-MC-JPCS |
| Disease (Sub Disease) | Solid Tumours |
| Diagnosis Stage | Relapsed/refractory |
| Location | QLD / VIC / WA |
| Sponsor | Eli Lilly and Company |
| Links | https://clinicaltrials.gov/ct2/show/NCT04238819 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 09/11/2020 |
| Sites | Perth Children's Hospital/ Royal Children's Hospital / Queensland Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 21 Years |
| International registry ID's | NCT04238819 |